Brepocitinib is an oral drug that inhibits certain enzymes involved in inflammation-;called tyrosine kinase 2 and Janus kinase 1-;and is being tested for the treatment of several immunological diseases.
/PRNewswire/ The Janssen Pharmaceutical Companies of Johnson & Johnson today announced new data from Phase 3 studies demonstrating patients treated with.
Adding the tumor necrosis factor inhibitor adalimumab to methotrexate because of a lack of efficacy or tolerability produced better results than escalating the methotrexate dose alone.